Q-omics provides the consensus-scored TRIM36-IT1 profile across patient tissues and cancer cell-line models. TRIM36-IT1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TRIM36-IT1 is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, TRIM36-IT1 RNA expression shows 6,744 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, COAD, and STAD as cancer lineages where TRIM36-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRIM36-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRIM36-IT1 survival associations across molecular data types. TRIM36-IT1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRIM36-IT1 RNA expression–survival associations across cancer types. High TRIM36-IT1 expression shows unfavorable associations in KIRC, LUSC, UCEC and CESC, but favorable associations in STAD and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TRIM36-IT1 RNA expression.
This table summarizes TRIM36-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for TRIM36-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRIM36-IT1 shows lower tumor expression in COAD, LUSC and KICH and higher tumor expression in PRAD and KIRC. The COAD box plot shows higher TRIM36-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p < 0.001).
This table shows molecular features associated with TRIM36-IT1 in patient tissues and cancer cell lines. In patient samples, TRIM36-IT1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
